Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study

Breast Cancer Research and Treatment

Volumn 43, Issue 1, 1997, Pages 7-14

  Amadori, Dino ^a   Volpi, Annalisa ^a   Maltoni, Roberta ^b   Nanni, Oriana ^b   Amaducci, Laura ^a   Amadori, Andrea ^c   Giunchi, Donata Casadei ^a   Vio, Antonio ^a   Saragoni, Ariele ^a   Silvestrini, Rosella ^d  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cell proliferation; Chemotherapy; Metastatic breast cancer; Predictive value

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA SYNTHESIS; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 8044224045     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005780107879     Document Type: Article

References (22)

1. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991
2. Neidhart JA: Hematopoietic colony-stimulating factors. Cancer 70: 913-920, 1992
3. Dogliotti L, Berruti A, Burriva T, Zola P, Barí MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Manzeglio C, Moro G, Sussio M, Perroni D: A randomized comparison of high dose epirubicin versus high dose epirubicin plus lonidamine in advanced breast cancer patients. First results from a cooperative group study. Int J Oncol 4: 741-746, 1994
4. Clark GM: Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 30: 117-126, 1994
5. Osborne CK: Receptors. In: Harris JR, Hellman S, Henderson JC, Kinne DW (eds), Breast Disease. Lippincott, Philadelphia, pp. 301-305, 1991
6. Meyer JS, Lee JY: Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res 40: 1890-1896, 1980
7. Paradiso A, Tommasi S, Mangia A, Lorusso V, Simone G, De Lena M: Tumor proliferate activity, progesterone receptor status, estrogen receptor level and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Res 50: 2958-2962, 1990
8. Nicholson RI, Bouzubar N, Walker KJ, et al.: Hormone sensitivity in breast cancer: influence of heterogeneity of estrogen receptor expression and cell proliferation. Eur J Cancer 7: 908-913, 1991
9. Silvestrini R, Daidone MG, Mastore M, et al.: Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 11: 1150-1155, 1993
10. Sulkes A, Livingston RR, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62: 513-515, 1979
11. Remvikos Y, Beuzeboc P, Zajdela A, Voillemot N, Magdelenat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383-1387, 1989
12. Bonadonna G, Valagussa P, Tancini G, et al.: Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancers. NCI Monogr. 1: 45-49, 1986
13. O'Reilly SM, Camplejohn RS, Millis RR, Rubens RD, Richards MA: Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node-positive breast cancer. Eur J Cancer 26: 1035-1038, 1990
14. Daidone MG, Silvestrini R, Canova S, Valagussa P, Bonadonna G: Tumor cell kinetics and course of node-positive breast cancer. Proc ASCO 8: 24, 1989
15. Muss H, Thor A, Kute T, et al.: erbB-2 (c-erbB-2: HER-2/ neu) and S-phase fraction predict response to adjuvant chemotherapy in patients with node-positive breast cancer: Cancer and Acute Leukemia Group B Trial 8869. Proc ASCO 12: 72, 1993
16. Amadori D, Volpi A, Callea A, Amaducci L, Morgagni S, Magni E, Nanni O: Clinical relevance of cell kinetics in breast cancer. Ann NY Acad Sci 698: 186-192, 1994
17. Silvestrini R, and the SICCAB Group for Quality Control of Cell Kinetic Determination: Feasibility and reproducibility of the 3H-thymidine labeling index in breast cancer. Cell Prolif 24: 437-445, 1991
18. Amadori D, Bonaguri C, Nanni O, et al.: Cell kinetics and hormonal features in relation to pathological stage in breast cancer. Breast Cancer Res Treat 18: 19-25, 1991
19. McGuire WL, Clark GM: Prognostic factors and treatment decisions in node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992
20. Early breast cancer trialists collaborative group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1-15, 1992
21. Skipper HE: Kinetic behavior versus response to chemotherapy. NCI Monogr 34: 2-14, 1971
22. Teixeira C, Reed JC, Prati MAC: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995.